Albitar



I am guessing that you did not get a chance to read the press release before you made that idiotic statement.
 
NeoTYPE?? Sounds like Caris Target Now to me (and that sucks). Sanger Sequencing the gold standard?? Its an old technology. There's already NextGen Sequencing and the next generation after that is already being worked on. 49% Revenue growth?? Net Income of $551,000, or $0.01 per share, vs. a loss of $(293,000), or ($0.01) per share in Q2 2011. Hey this is impressive, NOT :)
 
NeoTYPE?? Sounds like Caris Target Now to me (and that sucks). Sanger Sequencing the gold standard?? Its an old technology. There's already NextGen Sequencing and the next generation after that is already being worked on. 49% Revenue growth?? Net Income of $551,000, or $0.01 per share, vs. a loss of $(293,000), or ($0.01) per share in Q2 2011. Hey this is impressive, NOT :)

Where is the data on NEOCrap (type)? I have seen any e at all . What a bunch of dolts. Hey BG maybe Qunipiac should take away your PhD., oh that's right yoouuurrr not a PhD
 


Write your reply...